Planned maintenance may cause outages to the Department of Health and Aged Care’s network from 5:15 pm AEDT on 30 November to 10:00 pm AEDT on 1 December 2024. Access to TGA databases such as TBS Portal, ARTG and DAEN may be affected. We apologise for any inconvenience.
(Approval lapsed) Dobutrex (250mg/50mL (5mg/mL) solution for infusion vial
Section 19A approved medicine
(Approval lapsed) Dobutrex (250mg/50mL (5mg/mL) solution for infusion vial
Section 19A approval holder
Link Medical Products Pty Ltd ABN 73 010 971 516
Phone
1800 181 060
Approved until
Status
Expired
Medicines in short supply/unavailable
DBL DOBUTAMINE 250mg/20mL (as hydrochloride) injection - ARTG 46451
Indication(s)
Adults who require short-term treatment of cardiac failure secondary to acute myocardial infarction, or cardiac surgery
Additional information
Dobutrex 250mg/50mL (5mg/mL) solution for infusion vial is registered in Switzerland and is therefore packaged in German and French language. The active ingredient in German language 'Dobutaminum' is equivalent to 'Dobutamine' in English language. The strength dobutamine 250mg/50mL (5mg/1mL) are clearly distinguishable in English language. Please disregard the foreign language product insert and refer to the Australian Product Information for dobutamine available at https://www.ebs.tga.gov.au/